enGene Therapeutics Inc. (ENGN): Cash & Equivalents
$50.15M
As of 2025-10-31
$41.02M
As of 2026-07-31
+34.9%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $50.15M | -71.0% | 2025-12-22, Balance as of period end |
| 2024-10-31 | $173.00M | +112.2% | 2025-12-22, Balance as of period end |
| 2023-10-31 | $81.52M | +298.9% | 2024-12-19, Balance as of period end |
| 2022-10-31 | $20.43M | n/a | 2024-01-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $50.15M | -71.0% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $41.72M | +52.3% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $30.64M | -29.5% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $61.85M | +5.8% |
| Agenus Inc (AGEN) | 2025-12-31 | $3.00M | -92.6% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $152.41M | -14.7% |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $59.90M | -25.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $49.66M | -69.5% |
Compare ENGN, MGX, CMPX, IPSC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗